miRNA profile in pancreatic neuroendocrine tumors: Preliminary results.

Oana A Ciobanu, Vlad Herlea, Elena Milanesi, Maria Dobre, Simona Fica
Author Information
  1. Oana A Ciobanu: Department of Endocrinology and Diabetes, Elias Hospital, Bucharest, Romania. ORCID
  2. Vlad Herlea: Fundeni Clinical Institute, Bucharest, Romania.
  3. Elena Milanesi: Victor Babes National Institute of Pathology, Bucharest, Romania.
  4. Maria Dobre: Victor Babes National Institute of Pathology, Bucharest, Romania. ORCID
  5. Simona Fica: Department of Endocrinology and Diabetes, Elias Hospital, Bucharest, Romania.

Abstract

OBJECTIVE: Our understanding of the pathophysiology of pancreatic neuroendocrine tumors (PanNETs) remains incomplete, largely due to their historically underestimated incidence and the perception of these tumors as rare and slow-growing cancers. Additionally, conventional reliance on histological examination alone is gradually being supplemented by the exploration and introduction of molecular biomarkers, such as microRNAs (miRNAs). As miRNAs modulate the expression of multiple genes and pathways involved in the tumorigenesis of PanNETs, these biomarkers hold considerable promise for diagnosis and prognosis applications. In this study, we aimed to identify miRNAs as tissue markers associated with the diagnosis of PanNETs.
METHODS: We conducted a case-control study including: 7 PanNETs and 19 nontumoral pancreatic tissues obtained from Romanian patients. The samples underwent miRNA profiling via quantitative RT-PCR to assess the expression of 84 miRNAs. Our results were compared with those obtained by reanalyzing a public dataset. Furthermore, we structured our miRNA expression data according to their targeted mRNAs and their roles in signaling pathways.
RESULTS: Fourteen miRNAs (miR-1, miR-133a-3p, miR-210-3p, miR-7-5p, miR-10a-5p, miR-92b-3p, miR-132-3p, miR-221-3p, miR-29b-3p, miR-107, miR-103a-3p, let-7b-5p, miR-148a-3p, and miR-202-3p) were identified as differentially expressed by comparing PanNETs with pancreatic nontumoral tissues, with six miRNAs (miR-7-5p, miR-92b-3p, miR-29b-3p, miR-107, miR-103a-3p, and miR-148a-3p) also found in the public dataset analyzed. Bioinformatic analysis revealed that the 14 identified miRNAs target 17 genes. Reanalyzing two public gene expression datasets, five of these genes have been found differentially expressed in PanNET compared to controls.
CONCLUSIONS: Our preliminary results, albeit limited by a small sample size, highlighted a specific miRNA expression pattern able to distinguish tumoral from normal pancreatic tissue. The diagnostic performance of these miRNAs, matching with circulating miRNAs and validated in more homogeneous and large cohorts, could represent a starting point for improving the diagnostic accuracy of PanNETs.

Keywords

References

  1. Cancers (Basel). 2020 Sep 02;12(9): [PMID: 32887459]
  2. Biomolecules. 2023 Jan 03;13(1): [PMID: 36671481]
  3. Best Pract Res Clin Endocrinol Metab. 2023 Sep;37(5):101795 [PMID: 37429760]
  4. J Biochem Mol Toxicol. 2023 Dec;37(12):e23488 [PMID: 37597242]
  5. Am J Pathol. 2019 Jan;189(1):58-70 [PMID: 30558723]
  6. Oncotarget. 2017 Jul 25;8(30):49796-49806 [PMID: 28591701]
  7. Cancer Epidemiol. 2019 Dec;63:101598 [PMID: 31539715]
  8. Mol Cells. 2018 May 31;41(5):390-400 [PMID: 29754469]
  9. Cancer Discov. 2015 Dec;5(12):1296-313 [PMID: 26446169]
  10. Toxicol Rep. 2022 Apr 18;9:883-894 [PMID: 36518475]
  11. Int J Mol Sci. 2018 Sep 15;19(9): [PMID: 30223590]
  12. Gut. 2022 May;71(5):961-973 [PMID: 33849943]
  13. Mod Pathol. 2014 Apr;27(4):580-93 [PMID: 24072181]
  14. BMC Gastroenterol. 2020 May 6;20(1):137 [PMID: 32375666]
  15. Exp Mol Med. 2023 Jul;55(7):1314-1321 [PMID: 37430087]
  16. J Clin Oncol. 2008 Jun 20;26(18):3063-72 [PMID: 18565894]
  17. Clin Gastroenterol Hepatol. 2019 Oct;17(11):2212-2217.e1 [PMID: 30580091]
  18. Int J Mol Sci. 2022 Jan 20;23(3): [PMID: 35163032]
  19. Endocr Pathol. 2019 Jun;30(2):128-133 [PMID: 30767148]
  20. Exp Cell Res. 2017 Dec 15;361(2):316-323 [PMID: 29111166]
  21. Molecules. 2014 Feb 21;19(2):2458-68 [PMID: 24566314]
  22. Medicine (Baltimore). 2015 Dec;94(50):e2224 [PMID: 26683934]
  23. Mol Biol Rep. 2024 Nov 25;52(1):12 [PMID: 39585455]
  24. Ann Oncol. 2020 Jul;31(7):844-860 [PMID: 32272208]
  25. Endocr Relat Cancer. 2019 Jan 1;26(1):47-57 [PMID: 30021866]
  26. Exp Clin Endocrinol Diabetes. 2024 May;132(5):240-248 [PMID: 38354830]
  27. Gastroenterology. 2014 Feb;146(2):453-60.e5 [PMID: 24148618]
  28. Neuroendocrinology. 2018;106(1):47-57 [PMID: 28208131]
  29. BMC Bioinformatics. 2019 Nov 4;20(1):545 [PMID: 31684860]
  30. Cancer Manag Res. 2018 Nov 13;10:5629-5638 [PMID: 30519109]
  31. Endocr Relat Cancer. 2017 Jun;24(6):R223-R237 [PMID: 28389504]
  32. J Clin Med. 2022 Jun 30;11(13): [PMID: 35807078]
  33. Curr Probl Cancer. 2024 Oct;52:101131 [PMID: 39173542]
  34. Endocr Pathol. 2022 Mar;33(1):115-154 [PMID: 35294740]
  35. Oncol Lett. 2021 Jan;21(1):4 [PMID: 33240410]
  36. Neuroendocrinology. 2018;106(4):312-317 [PMID: 28848144]
  37. Pancreatology. 2023 Jun;23(4):429-436 [PMID: 37169669]
  38. Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii [PMID: 21349409]
  39. Endocr Relat Cancer. 2014 May 06;21(3):R153-63 [PMID: 24322304]
  40. Clin Exp Metastasis. 2024 Jun;41(3):163-186 [PMID: 38240887]
  41. Front Oncol. 2020 Jul 17;10:1187 [PMID: 32766159]
  42. Biochem Biophys Res Commun. 2024 Feb 5;695:149424 [PMID: 38169186]
  43. Hum Pathol. 2022 Nov;129:11-20 [PMID: 35872157]
  44. Neuroendocrinology. 2016;103(2):139-43 [PMID: 26730835]
  45. Lancet Oncol. 2008 Jan;9(1):61-72 [PMID: 18177818]
  46. Cancer Metastasis Rev. 2011 Mar;30 Suppl 1:3-7 [PMID: 21311954]
  47. CA Cancer J Clin. 2017 Mar;67(2):93-99 [PMID: 28094848]
  48. Biomed Res Int. 2021 Jul 07;2021:7590976 [PMID: 34307670]
  49. Pancreas. 2019 Mar;48(3):396-399 [PMID: 30747827]
  50. Genes (Basel). 2023 Aug 02;14(8): [PMID: 37628628]
  51. Nat Rev Cancer. 2015 Jun;15(6):321-33 [PMID: 25998712]
  52. Scand J Gastroenterol. 2019 Jan;54(1):69-75 [PMID: 30638086]
  53. J Clin Med. 2020 Sep 06;9(9): [PMID: 32899973]
  54. JAMA Oncol. 2017 Oct 01;3(10):1335-1342 [PMID: 28448665]
  55. Endocr Relat Cancer. 2015 Aug;22(4):657-64 [PMID: 26113608]
  56. J Clin Oncol. 2006 Oct 10;24(29):4677-84 [PMID: 16966691]
  57. J Clin Med. 2022 Jul 27;11(15): [PMID: 35955968]
  58. Mod Pathol. 2018 Aug;31(8):1302-1317 [PMID: 29487354]

MeSH Term

Humans
Pancreatic Neoplasms
MicroRNAs
Neuroendocrine Tumors
Case-Control Studies
Biomarkers, Tumor
Male
Female
Gene Expression Regulation, Neoplastic
Middle Aged
Gene Expression Profiling
Adult
Aged

Chemicals

MicroRNAs
Biomarkers, Tumor

Word Cloud

Created with Highcharts 10.0.0miRNAsPanNETspancreaticexpressionmiRNAneuroendocrinetumorsbiomarkersgenesdiagnosisresultspublicmolecularpathwaysstudytissuenontumoraltissuesobtainedcompareddatasetmiR-7-5pmiR-92b-3pmiR-29b-3pmiR-107miR-103a-3pmiR-148a-3pidentifieddifferentiallyexpressedfounddiagnosticprofileOBJECTIVE:understandingpathophysiologyremainsincompletelargelyduehistoricallyunderestimatedincidenceperceptionrareslow-growingcancersAdditionallyconventionalreliancehistologicalexaminationalonegraduallysupplementedexplorationintroductionmicroRNAsmodulatemultipleinvolvedtumorigenesisholdconsiderablepromiseprognosisapplicationsaimedidentifymarkersassociatedMETHODS:conductedcase-controlincluding:719RomanianpatientssamplesunderwentprofilingviaquantitativeRT-PCRassess84reanalyzingFurthermorestructureddataaccordingtargetedmRNAsrolessignalingRESULTS:FourteenmiR-1miR-133a-3pmiR-210-3pmiR-10a-5pmiR-132-3pmiR-221-3plet-7b-5pmiR-202-3pcomparingsixalsoanalyzedBioinformaticanalysisrevealed14target17ReanalyzingtwogenedatasetsfivePanNETcontrolsCONCLUSIONS:preliminaryalbeitlimitedsmallsamplesizehighlightedspecificpatternabledistinguishtumoralnormalperformancematchingcirculatingvalidatedhomogeneouslargecohortsrepresentstartingpointimprovingaccuracytumors:PreliminaryPancreaticoncology

Similar Articles

Cited By

No available data.